A Study of Acute Myocardial Infarction Using FDY-5301

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT03470441

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose other
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Faraday Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT03470441
Other papers using this trial's data
  • A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI International journal of cardiology, 2022-01-15 DOI, PubMed 34774885

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Hungary, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03470441. Randomized; triple masking; primary purpose other. Start 2017-10-27 (actual); primary completion 2018-07-14 (actual). Results posted on 2021-12-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Acute Myocardial Infarction Using FDY-5301
Condition
Acute Myocardial Infarction
Condition
STEMI
Intervention (Drug)
FDY-5301
Intervention (Other)
Placebo
Lead sponsor
Faraday Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03470441
Content hash
c385c133391503b60d1cbb3d6e10c8ea7f57f8eeebaa64a8166403e29b318b64